Phytochemical-Mediated Neuroprotection: Zea Mays (Corn Silk) Extract in Haloperidol-Induced Parkinsonism

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor dysfunction and dopaminergic neuron loss, affecting millions globally. Oxidative stress and neuroinflammation are key contributors to its pathogenesis. This study renders the antiparkinson potential of Zea mays (corn silk) Ethanolic extract in haloperidol-induced Parkinsonism in male albino mice. Corn silk, rich in flavonoids and polyphenols, is traditionally used for its antioxidant and anti-inflammatory properties, offering a potential alternative to address concerns about existing PD medications’ side effects. Physicochemical, acute toxicity, pharmacognostic, phytochemical, and behavioral analyses were performed. The extract’s antioxidant activity (DPPH assay) showed an IC₅₀ of 129.50 µg/mL (vs. 69.00 µg/mL for ascorbic acid). Bromocriptine was used as the standard drug, and extract doses of 75, 150, and 300 mg/kg were administered for 7 days. In mice, catalepsy was induced using haloperidol (4 mg/kg orally). Treatment groups received Bromocriptine (4 mg/kg) and ZMEECS at the doses of 75, 150, and 300 mg/kg. Orally. A bar test for catalepsy, a motor coordination test using the Rota rod, and locomotor activity measurements using an Actophotometer were carried out to assess behavioral changes. Acute toxicity testing as per the Organization for Economic Cooperation and Development 423(OECD423) on male albino mice revealed no harmful effects. Behavioral and biochemical parameters were assessed, alongside physicochemical, Pharmacognostic, and phytochemical evaluations. Results showed significant neuroprotective effects, suggesting Zea mays extract as a promising candidate for PD management. This study evaluates Zea mays corn silk extract as a natural therapy for Parkinson’s disease in mice, highlighting its antioxidant-mediated Neuroprotection. Further research is needed for clinical translation.